Betrixaban
CAS: 330942-05-7
Ref. TM-T4341
2mg | 46,00 € | ||
5mg | 69,00 € | ||
10mg | 94,00 € | ||
25mg | 169,00 € | ||
50mg | 278,00 € | ||
100mg | 446,00 € | ||
500mg | 975,00 € | ||
1ml*10 (DMSO) | 76,00 € |
Información del producto
- PRT054021
- Benzamide, N-(5-chloro-2-pyridinyl)-2-[[4-[(dimethylamino)iminomethyl]benzoyl]amino]-5-methoxy-
- Bevyxxa
- N-(5-Chloro-2-pyridinyl)-2-[[4-[(dimethylamino)iminomethyl]benzoyl]amino]-5-methoxybenzamide
- Prt 054021
Betrixaban (PRT054021) is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa [1]. It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity [3]. Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks for VTE [2]. VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients [4].
Propiedades químicas
Consulta técnica sobre: TM-T4341 Betrixaban
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.